Oppenheimer Asset Management Inc. Raises Stock Position in Boston Scientific Corporation $BSX

Oppenheimer Asset Management Inc. increased its stake in Boston Scientific Corporation (NYSE:BSX) by 2.2% during the 2nd quarter, HoldingsChannel reports. The firm owned 113,027 shares of the medical equipment provider’s stock after buying an additional 2,427 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Boston Scientific were worth $12,140,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in Boston Scientific by 15.4% in the second quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after acquiring an additional 3,932 shares during the period. MRA Advisory Group bought a new position in Boston Scientific in the second quarter worth approximately $273,000. Bank of New Hampshire raised its position in Boston Scientific by 552.0% in the second quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock worth $2,119,000 after acquiring an additional 16,699 shares during the period. NS Partners Ltd raised its position in Boston Scientific by 1.6% in the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock worth $37,143,000 after acquiring an additional 5,704 shares during the period. Finally, New England Research & Management Inc. bought a new position in Boston Scientific in the second quarter worth approximately $1,133,000. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 170,214 shares of company stock worth $17,548,337. Insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on BSX shares. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Raymond James Financial raised their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a research report on Thursday, July 24th. BTIG Research restated a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a research report on Wednesday, October 22nd. Finally, Barclays raised their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $123.77.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $101.08 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The company has a market cap of $149.78 billion, a P/E ratio of 54.06, a P/E/G ratio of 2.04 and a beta of 0.61. The firm’s fifty day moving average is $101.14 and its two-hundred day moving average is $102.12. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. Boston Scientific’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.